Anthropometric Measurements as Predictors of Low Birth Weight Among Tanzanian Neonates: A Hospital-Based Study
November 7, 2025
Brand Name :
No Data Available.
Synonyms :
Cefprozil
Class :
Antibiotics & Cephalosporins (second generation)
Dosage forms & Strengths
Suspension, Oral:
125 mg/5ml (150ml)
250 mg/5ml (150ml)
Tablet, oral
250 mg
500 mg
500
mg
Tablet
Orally
every 12 hrs
10
days
500
mg
Tablet
Orally
every 24 hours
10
days
If the infection is caused by S. pyrogenes, administer the dose for more than 10 days
500
mg
Tablet
Orally
every 24 hours
10
days
Dosage forms & Strengths
Suspension, Oral:
125 mg/5ml (150ml)
250 mg/5ml (150ml)
Tablet, Oral
250 mg
500 mg
7.5
mg/kg
Tablet
Orally
twice a day
10
days
Do not exceed 500 mg/dose
20
mg/kg
Tablet
Orally
4 times a day
10
days
Do not exceed 500 mg/dose
15
mg/kg
Tablet
Orally
twice a day
7 - 14
days
Refer to adult dosing
the interaction decreases the therapeutic effects of the vaccine
the interaction decreases the therapeutic effects of the vaccine
the interaction decreases the therapeutic effects of the vaccine
bazedoxifene conjugated estrogens
cefprozil may reduce the therapeutic effects of oral forms of conjugated estrogen by altering gut microflora
cefprozil will reduce the therapeutic effects of oral forms of hormones by altering gut microflora
cefprozil will reduce the therapeutic effects of oral forms of hormones by altering gut microflora
furosemide may enhance the therapeutic effects of cefprozil
the interaction may increase the therapeutic effects of cefprozil
the interaction may increase the therapeutic effects of cefprozil
cefprozil reduces the therapeutic effects of sodium picosulfate by altering metabolism
cephalosporins may decrease serum concentration and enhance nephrotoxicity of aminoglycosides
enhance the serum drug concentration by reducing renal clearance
enhance the serum drug concentration by reducing renal clearance
may raise the risk of nephrotoxicity
cefprozil increases the anticoagulant activity of warfarin by an unknown mechanism
it may diminish the excretion rate when combined with estradiol valerate resulting in a greater serum level
cefprozil has the potential to reduce the rate of excretion of idebenone, leading to an elevation in levels of serum
When loracarbef is used together with cefprozil, the risk or seriousness of nephrotoxicity is enhanced
When cefprozil is used together with piroxicam, this leads to increased risk or seriousness of nephrotoxicity
When cefmenoxime is used together with cefprozil, this leads to enhanced risk or seriousness of nephrotoxicity
When cefprozil is used together with proglumetacin, this leads to enhanced risk or seriousness of nephrotoxicity
When cefprozil is used together with benoxaprofen, this leads to enhanced risk or seriousness of nephrotoxicity
cefprozil leads to a reduction in the rate of excretion of eucalyptus oil which leads to increased level of serum
cefprozil leads to a reduction in the rate of excretion of pentaerythritol tetranitrate, which leads to an increased level of serum
cefprozil leads to a reduction in the rate of excretion of potassium acetate, which leads to an increased level of serum
cefprozil leads to a reduction in the rate of excretion of potassium perchlorate, which leads to an increased level of serum
cefprozil leads to a reduction in the rate of excretion of nitric oxide, which leads to an increased level of serum
When cefprozil is used together with difenpiramide, this leads to enhanced risk or seriousness of nephrotoxicity
cefprozil: it may decrease the excretion rate of isepamicin
cefprozil may decrease the excretion rate of almasilate, leading to higher serum levels
cefprozil might lead to a reduction in the rate of excretion of telavancin, potentially leading to elevated levels of serum
cefprozil increases the serum concentration of other drugs by reducing renal clearance
cefprozil increases the serum concentration of other drugs by reducing renal clearance
cefprozil increases the serum concentration of other drugs by reducing
the interaction reduces the effects of cefprozil
cefprozil increases the therapeutic effects of cyclopenthiazide
cefprozil will increase the effects of sulfasalazine
Actions:
Cefprozil stops bacteria from forming cell walls, which they need to survive, by binding to proteins, leading to cell rupture.
Spectrum:
Second-generation antibiotics like cefprozil work well against a broad range of bacteria, including Gram-positive and Gram-negative.
Frequency defined:
1% to 10%
Dizziness (1%)
Rashes (2%)
Pruritis (2%)
<1%
Drowsiness
Eosinophilia
Serum sickness
Thrombocytopenia
Increased serum creatinine
Blackbox warning
Exercise caution in penicillin-sensitive patients due to documented cross-sensitivity with β-lactam antibiotics, impacting up to 10% of those with a penicillin allergy.
Contraindication/Caution:
Contraindications
Cautions
Pregnancy consideration: Cefprozil is assigned under pregnancy category B. No adverse effects were observed in animal studies.
Lactation: Use with caution for breastfeeding females as it can be excreted in a small amount in breast milk.
Pregnancy category:
Pharmacology:
It’s proven effective in various conditions like tonsillitis, pharyngitis, respiratory and skin infections, and ear issues.
Pharmacodynamics:
Cefprozil stops bacterial cell wall formation by attaching to penicillin-binding proteins, crucial enzymes in peptidoglycan synthesis. This prevents peptidoglycan chain cross-linking, causing cell wall damage, cell breakdown, and bacterial death.
Pharmacokinetics:
Absorption
The bioavailability is 94%
The time to achieve peak effect is 1.5 hours
Distribution
Protein-bound is 35-45%
Metabolism
The metabolism occurs in liver.
Excretion and elimination
The half-life is 1.3 hours.
The drug is excreted 61 % in urine.
Administration
The drug is taken orally.
Patient information leaflet
Generic Name: Cefprozil
Pronounced: sef-pro-zil
Why do we use Cefprozil?
Pharyngitis, tonsillitis, otitis media, and simple skin infections are among the bacterial infections that can be treated with cefprozil.
To treat infections of the respiratory, skin, soft tissue, UTI, and ENT systems caused on by S. pneumoniae, H. influenzae, and staphylococci, S.